ENGTR1S Trademark

Trademark Overview


On Wednesday, July 14, 2021, a trademark application was filed for ENGTR1S with the United States Patent and Trademark Office. The USPTO has given the ENGTR1S trademark a serial number of 90828261. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Friday, December 20, 2024. This trademark is owned by GentiBio Inc.. The ENGTR1S trademark is filed in the Treatment & Processing of Materials Services, Pharmaceutical Products, and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of pharmaceuticals for others; Custom manufacturing of biological cells; consultation in the field of custom manufacture of pharmaceuticals and biological cells

Gene therapy products, namely, engineered cell platforms for immunotherapy purposes; Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders and allergic diseases and disorders

Scientific research; Pharmaceutical research; Medical research; Engineering of biological cells; genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering
engtr1s

General Information


Serial Number90828261
Word MarkENGTR1S
Filing DateWednesday, July 14, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateFriday, December 20, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 15, 2022

Trademark Statements


Goods and ServicesCustom manufacture of pharmaceuticals for others; Custom manufacturing of biological cells; consultation in the field of custom manufacture of pharmaceuticals and biological cells
Goods and ServicesGene therapy products, namely, engineered cell platforms for immunotherapy purposes; Pharmaceutical preparations for use in the treatment of autoimmune diseases and disorders, autoinflammatory diseases and disorders, alloimmune diseases and disorders and allergic diseases and disorders
Goods and ServicesScientific research; Pharmaceutical research; Medical research; Engineering of biological cells; genetic engineering of biological cells; Technological consultation services in the fields of engineering of biological cells; Laboratory research services in the field of immunology and cellular engineering

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateFriday, September 17, 2021
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, September 17, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, September 17, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGentiBio Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Party NameGentiBio Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBoston, MA 02111

Trademark Events


Event DateEvent Description
Thursday, April 7, 2022NON-FINAL ACTION WRITTEN
Saturday, July 17, 2021NEW APPLICATION ENTERED
Friday, September 17, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, April 3, 2022ASSIGNED TO EXAMINER
Thursday, April 7, 2022NON-FINAL ACTION E-MAILED
Thursday, April 7, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 5, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 5, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 5, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, October 7, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 26, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 15, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 15, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 10, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, July 10, 2023SOU TEAS EXTENSION RECEIVED
Monday, July 10, 2023SOU EXTENSION 1 FILED
Monday, July 10, 2023SOU EXTENSION 1 GRANTED
Wednesday, July 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 10, 2024SOU EXTENSION 2 FILED
Wednesday, January 10, 2024SOU EXTENSION 2 GRANTED
Friday, January 12, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 3, 2024SOU EXTENSION 3 GRANTED
Wednesday, January 10, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, July 2, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 3, 2024SOU EXTENSION 3 FILED
Wednesday, July 3, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, December 20, 2024SOU TEAS EXTENSION RECEIVED
Friday, December 20, 2024SOU EXTENSION 4 FILED
Saturday, December 21, 2024SOU EXTENSION 4 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED